<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5007551 Figure_3-B</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Validation of the TNF-RSC interacting proteins. A549 cells were stimulated with FLAG-TNF-&#945; for the indicated time and the TNF-RSCs were isolated as described in Figure 3A. TNF-&#945;-stimulation-dependent interaction of the indicated proteins was confirmed by isolating the TNF-RSC and blotting with the indicated antibodies. The amount of the analyzed proteins in the input material used for the TNF-RSC isolation is also shown.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_3-C</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Quantification of ubiquitin linkage peptides in the TNF-RSC. The box plot shows the relative abundance of K48, K63 and linear ubiquitin linkage-specific peptides in the TNF-RSCs isolated from TNF-&#945;-stimulated (15 min) and control cells quantified by SILAC-based MS.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_3-E</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. The list of proteins enriched in SPATA2pull-down. The table shows proteins that were enriched in GFP-SPATA2pull-down. The columns under "Unstimulated" shows SILAC ratios of the indicated proteins in SPATA2 pull-downs from unstimulated cells, whereas the columns under "Stimulated (TNF-&#945; 15 min)" shows SILAC ratios of the indicated proteins in SPATA2 pull-downs from cells stimulated with TNF-&#945; for 15 minutes.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_3-F</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Validation of TNF-&#945;-stimulation-independent association of SPATA2 with CYLD. GFP-SPATA2 was immunoprecipitated from unstimulated and TNF-&#945;-stimulated cells, and probed with CYLD antibody.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_3-G</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-G</infon>
    <infon key="sourcedata_figure_dir">Figure_3-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. HOIP interacts with SPATA2. FLAG-HOIP expressing A20.2J cells were SILAC labeled and FLAG-HOIP was immunoprecipitated from unstimulated cells and associated proteins were quantified using LC-MS/MS. The table contains proteins that were enriched in HOIPpull-down compared to control pull-down.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_3-H</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 3-H</infon>
    <infon key="sourcedata_figure_dir">Figure_3-H</infon>
    <passage>
      <offset>0</offset>
      <text>H. Validation of SPATA2 interaction with HOIP. GFP-tagged RNF31 was purified from unstimulated or TNF-a-stimulated (15 min) HCT116 cells and the immunoprecipitates were blotted with SPATA2, CYLD and GFP (HOIP) antibodies. The lower panels show expression of the indicated proteins in the input. The asterisk indicates unspecific band.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_4-B</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. The predicted PUB domain in the N-terminus of SPATA2 interacts with CYLD, but not with LUBAC or other TNF-RSC components. GFP-SPATA2 and the indicated deletion mutants were purified from A549 cells that were stimulated with TNF-&#945; for 15 minutes, and the enriched proteins were quantified using SILAC-based MS.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_4-C</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Validation of SPATA2 N-terminus interaction with CYLD. GFP-SPATA2 and the indicated deletion mutants were purified from A549 cells as described in Figure 5A, and association of CYLD was analyzed by immunoblotting. The lower panels show controls.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_4-D</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. The USP domain of CYLD interacts with SPATA2. STREP-FLAG-CYLD and the indicated deletion mutants were purified from A549 cells using Step-Tactin sepharose and blotted with SPATA2 antibody. The lower panels show controls.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_4-E</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. The C-terminus of SPATA2 interacts with HOIP. A549 cells were transiently transfected with GFP-tagged SPATA2, SPATA2 D200 and SPATA2 200*, and SPATA2 and the mutants were immunoprecipitated using GFP-trap beads. The immunoprecipitates were immunoblotted with HOIP, CYLD and GFP (HOIP) antibodies. The lower panels show input control, and the * shows unspecific band.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_5-B</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Effect of SPATA2 knockdown on association of proteins with TNF-RSC. The list shows SILAC ratios of TNF-RSC-associated proteins in control cells and SPATA2 knockdown cells. The proteins that showed reduced association with the TNF-RSC after SPATA2 knockdown are highlighted red.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_5-C</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Validation of SPATA2-dependent association of CYLD with the TNF-RSC. The TNF-RSC was purified under the indicated conditions and association of SPATA2, CYLD, RIPK1 and HOIP with the TNF-RSC was analyzed by immunoblotting. The input controls show expression of the analyzed proteins in cell lysates. The asterisk denotes unspecific bands.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_6-A</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. SPATA2 regulates TNF-a-induced NF-&#954;B activation. HEK293T cells were transfected with the SPATA2 siRNA (SMARTpool or with to individual siRNA) or a non-targeting control siRNA, and NF-kB activation was monitored with luciferase-based NF-kB reporter assays. Error bars specify the standard error of the mean (SEM) of three independent experiments. p** &lt; 0.05 (two-tailed, unpaired Student&#180;s t-test).</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_6-B</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Knockdown of SPATA2 enhances expression of the NF-&#954;B target genes. HEK293T cells were transfected with SPATA2 siRNA or a non-targeting control siRNA and the expression of the indicated mRNAs was measured in cells stimulated with TNF-a for 0, 3 and 6 hours with qPCR.</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_6-C</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. SPATA2 is involved in TNF-&#945;-induced necroptosis. SPATA2 was knocked down in L929 cells using RNAi, and cells were pretreated with DMSO, Z-VAD, or Z-VAD+NEC1 for 1 hour followed by treatment with TNF-&#945; for 2.5 hours. Cell viability was assessed with propidium iodide staining and flow cytometry. Knockdown of SPATA2 mRNA was verified using real time PCR. p** &lt; 0.05 (two-tailed, unpaired Student&#180;s t-test).</text>
    </passage>
  </document>
  <document>
    <id>5007551 Figure_6-D</id>
    <infon key="sourcedata_document">2015</infon>
    <infon key="doi">10.15252/embj.201694300</infon>
    <infon key="pmc_id">5007551</infon>
    <infon key="figure">Figure 6-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Knockdown of SPATA2 reduces phosphorylation of MLKL in TNF-&#945;-induced necroptosis. TNF-&#945;-dependent necroptosis was induced in L929 as described in Figure 6C. Phosphorylation of MLKL was analyzed using S358 phospho-specific antibody.</text>
    </passage>
  </document>
</collection>
